- Open Access
The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
Biomarker Research volume 11, Article number: 11 (2023)
BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPortal, we demonstrated that patients with Class3 BRAF mutations had the best survival outcomes compared to the other two subgroups. These findings promoted the development of anti-BRAF strategies by distinguishing BRAF mutant subgroups.
To the editor,
BRAF mutation is considered to be an oncogenic driver in colorectal cancer (CRC) and V600E is the most dominant BRAF mutation . Mutations occurring at V600 of BRAF such as V600E/K/D/R/M cause the expression of RAS-independent active monomeric proteins, which are grouped as Class1 BRAF mutations. Other non-V600 BRAF mutations can be classified based on signaling mechanism and kinase activity, including RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3) [2, 3]. The molecular features of the three classes of BRAF mutations varied and could lead to different treatment strategies . For instance, canonical BRAF inhibitors, such as encorafenib and vemurafenib, directly target the monomeric BRAF protein, to which only the patients carrying Class1 BRAF mutations were sensitive . Thus, comprehensively studying the distinctions in signaling transduction and other genetic features among patients carrying different classes of BRAF mutations may inspire the combination strategies of existing BRAF inhibitors and other targeted therapies. Also, the development of next-generation BRAF inhibitors targeting the dimeric BRAF protein is urgently needed.
In this multicenter retrospective study, the treatment-naïve tumor samples with BRAF mutations collected from 328 CRC patients were analyzed using next-generation sequencing (NGS, Fig.S1A; Class1: N = 246, Class2: N = 29, Class3: N = 53). The incidence of Class1 mutation in this cohort (75%, 246/328) was comparable to previous studies (79%, 92/117) . All Class1 BRAF mutations were V600E, while Class2 and Class3 mutations were predominantly G469 (53%) and D594 (56%), respectively (Fig. 1A). No differences in patient’s age, sex, and stage were observed among the three subgroups, but the anatomical location of the tumor differed among subgroups, particularly between Class1 and Class3 (p = 0.027, Table S1).
Somatic mutation profiling revealed that the most frequently mutated gene in Class1 and Class3 was TP53 (66.9% and 84.9%) while that in Class2 was APC (75.9%, Fig.S1B). KRAS, NRAS, and APC mutations were significantly enriched in the Class2/3 subgroups, while the mutational frequency of RNF43 was significantly higher in the Class1 subgroup. The genes involved in PI3K signaling pathway, including PTEN and AKT3, were significantly more frequently mutated in Class2 (Fig. 1B). In addition, Wnt or RTK/RAS signaling pathway alterations were significantly more common in Class2/3 subgroups compared to Class1, but pathogenic cell cycle pathway alterations were only detected in Class1/2 (Fig. 1C). Then, we compared the allele frequencies (AFs) of BRAF mutations and concurrent KRAS/NRAS/HRAS mutations that were reported to cause RAS signaling activation. As shown in Fig. 1D, the proportions of patients harboring RAS activating mutations in Class2 (31%) and Class3 (43%) were significantly higher than that in Class1 (7%, p < 0.001). In Class2/3, the AFs of BRAF mutations were commonly lower than the concurrent RAS activating mutations, indicating that these BRAF mutations might be subclonal. Furthermore, the mutational signature associated with nucleotide excision repair (NER) was significantly enriched in tumors with Class1 BRAF mutations, but the mutational signature related to the apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) enzyme was more commonly identified in Class3 compared to Class1 (Fig. 1E). The tumor mutational burden (TMB) of patients harboring BRAF mutations was significantly higher than that of patients with wildtype BRAF (median: 5.8), while Class2 BRAF-mutant tumors demonstrated non-significantly higher TMB than the other two subgroups (median: 10.4 vs. 7.6 and 8.4, Fig. 1F). However, microsatellite instability-high (MSI-H) tumors were slightly more common in Class1 compared to Class2/3 (Class1: 11% vs. Class2: 7% vs. Class3: 4%, Fig. 1G), but significantly when compared with wildtype subgroup (5%, p < 0.001).
Due to the lack of survival data in our cohort, we utilized an external dataset from cBioPortal which contained 455 unresectable metastatic CRC patients to investigate the association between prognosis and BRAF mutation subtypes (wildtype: N = 396, Class1: N = 38, Class2: N = 8, Class3: N = 8, Others: N = 5) . First, similar analyses on genetic characteristics including concurrent RAS-activating mutations, MSI-H, and TMB levels were performed to validate the findings observed in our cohort. As shown in Fig. 2A, Class1 BRAF V600E mutation was not concurrent with any RAS activating mutations, which were detected in 62% of patients with wildtype BRAF and 50% of those in Class3 (p < 0.001). Similar to our cohort, the proportion of MSI-H patients was the highest in Class1 (24%, Fig. 2B). Even though no significant difference in TMB was observed among those subgroups in this external cohort, a trend of higher TMB in BRAF-mutated tumors than BRAF-wildtype tumors was observed (Fig. 2C), which also supported the genetic similarity between the two cohorts. Then, we investigated the survival outcomes of patients with Class1/2/3 BRAF mutations. As shown in Fig. 2D-E, patients with Class1 BRAF mutants had the worst progression-free survival (PFS; median: 5.0 months) and overall survival (OS; median: 12.7 months) whereas patients in Class3 demonstrated the best prognosis (median PFS: 7.3 months; median OS: 31.9 months). Considering the restricted cohort size for patients with Class2/3 BRAF mutations, we exploited a second independent dataset for survival analysis . A similar trend of better OS was observed in patients with Class 3 BRAF mutations versus the other two subtypes (Fig. S2), although the sample size of this cohort was still limited (Class1: N = 27, Class2: N = 5, Class3: N = 8) due to the low frequency of Class2/3 BRAF mutations.
Matsumoto et al.  reported a strong association between RNF43 mutations and BRAF V600E, which was consistent with our observation (Fig. 1B). However, other genes in the Wnt signaling pathways, e.g., APC, AMER1, and CTNNB1 showed the opposite trend and the percentage of patients with alterations in Wnt pathway were significantly higher in Class 2/3 than Class1 (Fig. 1C). Notably, the TMB levels of each BRAF subgroup in our cohort were not in accordance with the public cBioPortal cohort , which might be due to the restricted cohort size and the different targeted NGS panels used for TMB estimation. In addition, the large difference in cohort size between Class1 and Class2/3 both in our cohort and the external dataset should be noted, implying the warrant of further validation with a larger sample size of Class2/3 BRAF mutations. Also, the zygosity status (homozygous vs. heterozygous) of the BRAF mutations was not evaluated in the current NGS pipeline and the external dataset, which was reported to be associated with the response to BRAF inhibitor treatment . Thus, to comprehensively interpret treatment sensitivity and prognosis between different zygosity status, further studies are needed. The prognosis of three BRAF subgroups analyzed here was supported by a previous study that reported the longest PFS and OS in patients with Class3 BRAF mutations . As the available BRAF inhibitors only target BRAF V600 mutations, patients with Class2/3 BRAF mutations are not sensitive to them . Encouragingly, a second-generation BRAF inhibitor, BGB-3245, targeting both monomer and dimer forms of active BRAF proteins is in the early phase of clinical trial (NCT04249843), which might expand the benefits to patients with non-V600 BRAF mutations. In addition, due to the high dependency on EGFR signaling, Class3 BRAF mutations were proven to respond to anti-EGFR therapy, indicating a bright future of combination therapies in patients with non-V600 BRAF mutations .
In conclusion, the CRC tumors harboring Class1 BRAF mutations demonstrated more unique genetic profiles than those with Class2/3 mutations and patients with Class3 BRAF mutations had the best survival outcomes among all BRAF subgroups. Our findings suggested the potential differential treatment strategies for patients with different BRAF mutation subtypes and emphasized the urgency of the development of anti-BRAF drugs, especially targeting the active dimeric BRAF proteins.
Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.
Tumor mutation burden
Nucleotide excision repair
Apolipoprotein B mRNA editing catalytic polypeptide-like enzyme
Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, et al. (Non-V600) BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal Cancer. J Clin Oncol. 2017;35(23):2624–30.
Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, et al. Class 1, 2, and 3 BRAF-Mutated metastatic colorectal Cancer: a detailed clinical, pathologic, and molecular characterization. Clin Cancer Res. 2019;25(13):3954–61.
Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019;9(3):329–41.
Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, et al. Response to Anti-EGFR therapy in patients with BRAF non-V600-Mutant metastatic colorectal Cancer. Clin Cancer Res. 2019;25(23):7089–97.
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548(7666):234–8.
Mondaca S, Walch H, Nandakumar S, Chatila WK, Schultz N, Yaeger R. Specific mutations in APC, but not alterations in DNA damage response, associate with outcomes of patients with metastatic colorectal Cancer. Gastroenterology. 2020;159(5):1975–8. e4.
Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, et al. Clinical sequencing defines the genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell. 2018;33(1):125–36. e3.
Matsumoto A, Shimada Y, Nakano M, Oyanagi H, Tajima Y, Nakano M, et al. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer. Oncol Rep. 2020;43(6):1853–62.
Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, et al. Systems Analysis of adaptive responses to MAP kinase pathway blockade in BRAF Mutant Melanoma. PLoS ONE. 2015;10(9):e0138210.
Sahin IH, Klostergaard J. BRAF mutations as actionable targets: a paradigm shift in the management of Colorectal Cancer and Novel Avenues. JCO Oncol Pract. 2021;17(12):723–30.
We would like to thank the patients and their families who consented to participate in this study, as well as the investigators and research staff involved.
This work was supported by the Science Foundation of the Postdoctoral Department of Heilongjiang Province (No.LBH-Q21118), Haiyan Research Funding of the Harbin Medical University Cancer Hospital (No. JJZD2021-03), and Program of Science and Technology of Sichuan Province (No.2021YFQ0037).
Ethics approval and consent to participate
This study was approved by the Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital (SCCHEC-02-2022-058). Written informed consent was collected from each patient prior to sample collection.
Consent for publication
Written informed consent was obtained from the patients for publication of this study.
Yutong Ma, Yaru Zhang, Mengmeng Wu, Chunman Wu, Qiuxiang Ou, Xue Wu, and Yang Shao are employees of Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China. The other authors declare no competing financial interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1:
Supplementary Methods. Supplementary Table S1. Clinical characteristics of patients. Supplementary Figure S1. The overview of patients enrolled in this study and the concurrent gene/pathway alterations. (A) A total of 328 colorectal patients whose treatment-naïve tumor samples harboring BRAF mutations from the database are included in this study. (B) The oncoprint of the most frequently concurrent gene mutations (top panel) and pathway alterations (bottom panel) are shown as legend by BRAF classes. Supplementary Figure S2. Patients with Class 3 BRAF mutations demonstrated longer OS compared to those with Class1/2 BRAF mutations. Patients’ overall survival (OS) data from an additional external cohort were analyzed based on the Kaplan-Meier modeling. NR, not reached.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Chen, Y., Sun, H., Deng, Y. et al. The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses. Biomark Res 11, 11 (2023). https://doi.org/10.1186/s40364-022-00443-8
- Colorectal cancer
- Next-generation sequencing